GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
|
Compound class:
Synthetic organic
Comment: RMC-113 is reported as an inhibitor of the lipid kinases PIP4K2C and PIKfyve [1].
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
|||||||||||||||||||||||||||||||||||
| Bioactivity Comments |
| RMC-113 suppresses the replication of multiple RNA viruses including SARS-CoV-2 in human lung organoids, likely through reversing autophagic flux impairment induced by PIP4K2C interaction with CoV nonstructural protein 6 (nsp6) [1]. In a cell-based kinome profiling analysis RMC-113 dose-dependently binds to PIKfyve, PIP4K2A, PIP4K2B, and PIP4K2C, but no/very low potency inhibition of kinase activity for PIP4K2A and PIP4K2B was detected in orthogonal kinase activity assays. |
| Selectivity at enzymes | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Key to terms and symbols | Click column headers to sort | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||